XERIS BIOPHARMA HOLDINGS INC (XERS)

US98422E1038 - Common Stock

1.75  +0.05 (+2.94%)

After market: 1.75 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
49.6M
143.14%		110.2M
122.18%		163.914M
48.74%		188.12M
14.77%
EBITDA
YoY % growth
-104.62M
-27.38%		-59.56M
43.07%		-31.68M
46.81%		-7.344M
76.82%		N/AN/A
EBIT
YoY % growth
-106.5M
-27.39%		-71.8M
32.58%		-44.01M
38.70%		-30.377M
30.98%
Operating Margin
-214.72%-65.15%-26.85%-16.15%
EPS
YoY % growth
-1.52
33.33%		-0.70
53.95%		-0.45
35.71%		-0.39
12.73%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.12
0.83%
Revenue
Q2Q % growth		42.651M
28.47%
EBITDA
Q2Q % growth		-6.528MN/AN/AN/AN/A
EBIT
Q2Q % growth		-10.16M
23.49%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.10 -0.100.00-0.04%
Q3 2023
Q2Q % growth		 -0.09
43.75%		-0.120.0323.94%
Q2 2023
Q2Q % growth		 -0.14
26.32%		-0.13-0.01-7.65%
Q1 2023
Q2Q % growth		 -0.12
52.00%		-0.170.0529.76%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 44.39M
33.95%		44.423M-33K-0.07%
Q3 2023
Q2Q % growth		 48.32M
62.53%		41.905M6.415M15.31%
Q2 2023
Q2Q % growth		 38.01M
50.18%		35.534M2.476M6.97%
Q1 2023
Q2Q % growth		 33.2M
50.43%		31.381M1.819M5.80%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0.71% -22.81% -41.54% -31.85%
Revenue0.86% -1.27% -1.9% -0.52%